Similarly, a large body of research evidence has indicated that administration of gut microbiota, such as Akkermansia and Bifidobacterium, influences the BA metabolism and alters the intestinal microbiota, whereas a reduction in the LZys1 group including species of Akkermansia demonstrated to contribute to the regulation of BA profiles via the FXR–FGF15 axis in non-alcoholic fatty liver disease (NAFLD) (42). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.